Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy
about
Clinical factors related to brain structure in HIV: the CHARTER studyFacial emotion recognition impairments in individuals with HIVRole of neuroimaging in HIV-associated neurocognitive disordersMapping fetal brain development in utero using magnetic resonance imaging: the Big Bang of brain mapping.Impact of apolipoprotein E ε4 and HIV on cognition and brain atrophy: antagonistic pleiotropy and premature brain aging.Neuroimaging of HIV-associated neurocognitive disorders (HAND)Conditional Tat protein brain expression in the GT-tg bigenic mouse induces cerebral fractional anisotropy abnormalities.Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individualsNuclear factor-kappa B family member RelB inhibits human immunodeficiency virus-1 Tat-induced tumor necrosis factor-alpha production.Predictors of CNS injury as measured by proton magnetic resonance spectroscopy in the setting of chronic HIV infection and CART.Cerebral FDG-PET scanning abnormalities in optimally treated HIV patients.Ibudilast, a pharmacologic phosphodiesterase inhibitor, prevents human immunodeficiency virus-1 Tat-mediated activation of microglial cellsDiffusion tensor and volumetric magnetic resonance measures as biomarkers of brain damage in a small animal model of HIV.In vitro downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: therapeutic implication for HIV brain infection.Comparison of scales to evaluate the progression of HIV-associated neurocognitive disorder.Neuroimaging studies of the aging HIV-1-infected brainEarly suppressive antiretroviral therapy in HIV infection is associated with measurable changes in the corpus callosum.Structural gray matter change early in male patients with HIV.The role of medical imaging in defining CNS abnormalities associated with HIV-infection and opportunistic infectionsMicro-structural brain alterations in aviremic HIV+ patients with minor neurocognitive disorders: a multi-contrast study at high field.Regional areas and widths of the midsagittal corpus callosum among HIV-infected patients on stable antiretroviral therapies.Disturbance in cerebral spinal fluid sphingolipid content is associated with memory impairment in subjects infected with the human immunodeficiency virusChanges in brain anatomy during the course of posttraumatic stress disorderPlasma cytokine levels are related to brain volumes in HIV-infected individuals.Multimodal neuroimaging evidence of alterations in cortical structure and function in HIV-infected older adults.Independent effects of HIV, aging, and HAART on brain volumetric measures.Regional brain structural dysmorphology in human immunodeficiency virus infection: effects of acquired immune deficiency syndrome, alcoholism, and ageDendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.Effects of HIV and early life stress on amygdala morphometry and neurocognitive function.Cell-free mitochondrial DNA in CSF is associated with early viral rebound, inflammation, and severity of neurocognitive deficits in HIV infectionCurrent understanding of HIV-associated neurocognitive disorders pathogenesis.Progressive cerebral injury in the setting of chronic HIV infection and antiretroviral therapy.The effects of HIV and combination antiretroviral therapy on white matter integrityEffects of HIV and childhood trauma on brain morphometry and neurocognitive function.Mapping white matter integrity in elderly people with HIVIncreases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infectionDisrupted cerebral metabolite levels and lower nadir CD4 + counts are linked to brain volume deficits in 210 HIV-infected patients on stable treatmentHIV clades B and C are associated with reduced brain volumetricsRegional brain gray and white matter changes in perinatally HIV-infected adolescents.A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects.
P2860
Q24603224-92C3BB38-E4B3-4F85-A73D-54E7AE994A4CQ24628127-8298F1FE-E4CF-42DA-BA9B-83ED63048C83Q26852705-CEDF2FF7-C970-449A-9886-1362E1EF031AQ30453512-DF35F861-EDAD-4165-AE96-F7ACD76141DBQ30462497-0DE93C5E-D21D-4ABD-9776-249B11656D2EQ30854917-B8FC548A-BC14-45B0-BD76-E624A63479B8Q30885921-DE570E22-7BF5-4270-B7A5-A8B22BD60D53Q33614467-4B25CFD0-4281-40C2-AC6A-4C843E1A292BQ33649838-1810E5B3-80D7-46F2-9D06-5951DEF6E515Q33699222-8B69E483-2B71-4956-8AAB-53AD82677A4BQ33728851-13CEEBB3-4DDC-4581-8C15-0091BF867AB8Q33873538-2BF3C50A-DDAE-4CDF-9B57-E91B76620791Q34075695-07C65067-0A8A-478D-8E13-F23E80CED012Q34103125-4A06A334-325E-44A1-8C2C-FE1BB42E8736Q34103216-A8CFE312-8359-4A36-A6FF-C779037E5C47Q34288457-B47CEB73-C527-405B-8BA8-B6ADE3635717Q34389419-7A972C64-42E0-4E90-9BAC-87D3284A0B7CQ34547989-1E31A7C5-87C2-4981-B7E5-B6DBC998DF56Q34787585-0CB2995D-5637-4C3D-8D21-88DAA2BB4B4EQ34988471-C38FF584-708A-4B64-A7E0-9C8D78134C78Q35023780-6B5C88C2-6C03-489A-8282-FAB2B41F81DBQ35130214-E5EACD53-CFCA-43C8-862B-7CCFC28E9076Q35220352-001C0EDE-8FF1-4583-8DD7-8BA194275907Q35572270-4717CBDF-DF39-488E-944D-07E6B221A431Q35819368-792F6618-2520-424F-BC4E-E68D05BD8F87Q35827867-B5D12FCF-176E-491F-8AA0-34DA20631A2BQ36087139-26EF9165-9C84-480C-8C29-018F3D4902E6Q36406259-41C67D0E-C07E-4CBB-8525-302C4E9F3110Q36619628-3F623563-E308-4603-BDAD-46E0969DFCA2Q36888321-4AD04D5D-E44B-4DE5-9A00-430C93DA579EQ36932005-1DA7D510-2EDF-4EB9-B0ED-A3FAC01B6F5EQ37086701-9FD00C24-CF62-4F1A-9BD2-C6C126C2DFF1Q37118352-CF613A50-AB5C-4519-94D6-D441AB5AA0DFQ37123124-B5D505F5-C5B3-42CA-9CE3-9F4A11887DCAQ37179026-65801ADC-9595-45F7-8EB5-4D76AAD1CB20Q37181324-C5C24771-3BBC-4FE4-8E12-CE05B0412F86Q37217155-4F87F955-949B-490C-9842-E3565C233850Q37354426-7C01EBC7-B26D-4F72-B475-46E99C9BFA3DQ37417723-5D3768A0-9945-4CF2-AD18-25B91B5917F9Q37463446-1ECB7FB6-3D8D-4381-9F16-2CDD17B83E8F
P2860
Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Evidence for ongoing brain inj ...... ed with antiretroviral therapy
@ast
Evidence for ongoing brain inj ...... ed with antiretroviral therapy
@en
Evidence for ongoing brain inj ...... ed with antiretroviral therapy
@nl
type
label
Evidence for ongoing brain inj ...... ed with antiretroviral therapy
@ast
Evidence for ongoing brain inj ...... ed with antiretroviral therapy
@en
Evidence for ongoing brain inj ...... ed with antiretroviral therapy
@nl
prefLabel
Evidence for ongoing brain inj ...... ed with antiretroviral therapy
@ast
Evidence for ongoing brain inj ...... ed with antiretroviral therapy
@en
Evidence for ongoing brain inj ...... ed with antiretroviral therapy
@nl
P2093
P2860
P1476
Evidence for ongoing brain inj ...... ed with antiretroviral therapy
@en
P2093
C Studholme
D J Meyerhoff
H Lampiris
J Rothlind
M W Weiner
V A Cardenas
P2860
P2888
P304
P356
10.1080/13550280902973960
P407
P50
P577
2009-07-01T00:00:00Z
P5875
P6179
1018595014